dc.contributor.author | Wong, YNS | |
dc.contributor.author | Joshi, K | |
dc.contributor.author | Pule, M | |
dc.contributor.author | Peggs, KS | |
dc.contributor.author | Swanton, C | |
dc.contributor.author | Quezada, SA | |
dc.contributor.author | Linch, M | |
dc.date.accessioned | 2018-02-20T15:17:59Z | |
dc.date.issued | 2017-06 | |
dc.identifier.citation | The Lancet Oncology, 2017, 18 (6), pp. e341 - e353 | |
dc.identifier.issn | 1470-2045 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1449 | |
dc.identifier.doi | 10.1016/s1470-2045(17)30327-3 | |
dc.format.extent | e341 - e353 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | Elsevier BV | |
dc.title | Evolving adoptive cellular therapies in urological malignancies | |
dc.type | Journal Article | |
rioxxterms.versionofrecord | 10.1016/s1470-2045(17)30327-3 | |
rioxxterms.licenseref.startdate | 2017-06 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | The Lancet Oncology | |
pubs.issue | 6 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 18 | |
pubs.embargo.terms | Not known | |
dc.contributor.icrauthor | Marsden, | en |